Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 961 to 970 of 1090 total matches.
Once-Monthly Subcutaneous Buprenorphine (Sublocade) for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • Feb 26, 2018 (Issue 1541)
Strategy (REMS) program before they can order and
dispense Sublocade.
DRUG INTERACTIONS — Concurrent use ...
The FDA has approved a subcutaneous (SC)
extended-release formulation of the mu-opioid
receptor partial agonist and kappa-opioid receptor
antagonist buprenorphine (Sublocade – Indivior)
for once-monthly treatment of moderate to severe
opioid use disorder. Sublocade is the first injectable
buprenorphine product to be approved in the US.
Buprenorphine is also available in sublingual
formulations with or without the opioid antagonist
naloxone, in a buccal formulation with naloxone, and
as a subdermal implant (Probuphine).
Fenfluramine (Fintepla) for Dravet Syndrome
The Medical Letter on Drugs and Therapeutics • Aug 09, 2021 (Issue 1630)
.
DRUG INTERACTIONS — Coadministration with
stiripentol and clobazam increases plasma concentrations ...
The FDA has approved fenfluramine oral solution
(Fintepla – Zogenix) for treatment of seizures in
patients ≥2 years old with Dravet syndrome. It is the
third drug to be approved for this indication. Stiripentol
(Diacomit) and cannabidiol (Epidiolex), a purified
product derived from marijuana, were approved earlier.
Semaglutide (Wegovy) for Weight Loss
The Medical Letter on Drugs and Therapeutics • Jul 12, 2021 (Issue 1628)
syndrome type 2.
DRUG INTERACTIONS — By slowing gastric emptying,
semaglutide can delay the absorption ...
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide, previously approved
by the FDA as Ozempic to treat type 2 diabetes and
to reduce the risk of major adverse cardiovascular
events in adults with type 2 diabetes and established
cardiovascular disease, has now been approved in
a higher dose as Wegovy (Novo Nordisk) for chronic
weight management in adults with or without type 2
diabetes who have a body mass index (BMI) ≥30 kg/m2
or a BMI ≥27 kg/m2 and ≥1 weight-related comorbidity
(e.g., hypertension, dyslipidemia). An oral formulation
of semaglutide...
Fluticasone Furoate (Arnuity Ellipta) for Asthma
The Medical Letter on Drugs and Therapeutics • May 25, 2015 (Issue 1469)
;
no adequate studies in women) for use during
pregnancy.
DRUG INTERACTIONS — Fluticasone furoate ...
The FDA has approved Arnuity Ellipta (GSK), a single-agent
inhaler containing the corticosteroid fluticasone
furoate, for once-daily maintenance treatment of
asthma in patients ≥12 years old. Fluticasone furoate
is also available in combination with the long-acting
beta2-agonist vilanterol as Breo Ellipta for treatment
of asthma and COPD.
Sacubitril/Valsartan (Entresto) for Heart Failure
The Medical Letter on Drugs and Therapeutics • Aug 03, 2015 (Issue 1474)
function
and increase fetal and neonatal morbidity and death.
DRUG INTERACTIONS — Concurrent use ...
The FDA has approved Entresto (Novartis), an oral
fixed-dose combination of the neprilysin inhibitor
sacubitril and the angiotensin receptor blocker (ARB)
valsartan, to reduce the risk of cardiovascular death
and heart failure hospitalization in patients with
heart failure with reduced ejection fraction. Sacubitril
is the first neprilysin inhibitor to become available in
the US.
Statins for High-Risk Patients without Heart Disease or High Cholesterol
The Medical Letter on Drugs and Therapeutics • Jan 02, 2006 (Issue 1225)
significant.
8
ADVERSE EFFECTS AND DRUG INTERACTIONS —
All statins are generally well tolerated. The risk ...
The FDA recently approved the use of atorvastatin (Lipitor) to reduce the risk of heart attack and stroke in patients without heart disease who have type 2 diabetes plus other risk factors, with or without hypercholesterolemia. The agency also approved the drug's use to reduce the risk of stroke in high-risk nondiabetic patients without heart disease, whether or not they have hypercholesterolemia. Similar indications were previously approved for simvastatin (Zocor).
Continuous Glucose Monitoring
The Medical Letter on Drugs and Therapeutics • Feb 12, 2007 (Issue 1254)
of Michigan Medical School
Eric J. Epstein, M.D., Albert Einstein College of Medicine
DRUG INTERACTIONS ...
A variety of glucose monitoring devices have been used in an effort to reduce the hypoglycemia and wide glucose excursions that complicate insulin treatment of diabetes. Since the last Medical Letter issue reviewing such devices, more continuous glucose monitoring (CGM) systems have become available. Five devices available now, and two expected to be marketed soon, are listed in the table on page 14. The FDA has approved continuous glucose devices only for the observation of glucose trends.
Fluvoxamine for Obsessive-Compulsive Disorder
The Medical Letter on Drugs and Therapeutics • Feb 17, 1995 (Issue 942)
interactions
with psychiatric and other drugs may be troublesome.
THE MEDICAL LETTER (ISSN 1523-2859 ...
Fluvoxamine (Luvox - Solvay), a selective serotonin reuptake inhibitor (SSRI), has been approved for treatment of obsessive-compulsive disorder (OCD) by the US Food and Drug Administration. Fluoxetine (Prozac), another SSRI antidepressant, and clomipramine (Anafranil), a tricyclic antidepressant that also inhibits serotonin reuptake, are the only other drugs available for this indication in the USA. Antidepressants that do not inhibit serotonin reuptake have not been effective for treatment of this condition.
Doxacurium
The Medical Letter on Drugs and Therapeutics • Jul 26, 1991 (Issue 849)
Atracurium Arduan correction Angina pectoris bepridila for Anectine Dilantin Interactions drug ...
Doxacurium (Nuromax - Burroughs Wellcome), a new, long-acting, nondepolarizing neuromuscular blocking agent, is now available in the USA for use as a skeletal muscle relaxant during general anesthesia and for endotracheal intubation. Although small decreases in heart rate and mean arterial pressure occur in some patients who receive doxacurium, clinical studies have found no adverse cardiovascular effects in patients with heart disease receiving up to three times the usual effective dose (CM Stoops et al, Anesthesiology, 69:365, 1988; DJ Murray et al, Anesthesiology, 69:472, 1988; RS...
Exenatide (Byetta) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jun 06, 2005 (Issue 1210)
it as category C for use during pregnancy.
DRUG INTERACTIONS — Because it slows gastric
emptying; exenatide can ...
Exenatide injection (Byetta - Amylin/Lilly), a synthetic peptide that stimulates release of insulin from pancreatic beta cells, has been approved by the FDA as adjunctive therapy for patients with type 2 diabetes who have not achieved optimal glycemic control on metformin (Glucophage, and others), a sulfonylurea, such as glyburide (DiaBeta, and others), or both. Exenatide is not indicated for use with insulin.